Find in Library
Search millions of books, articles, and more
Indexed Open Access Databases
Development and Preclinical Investigation of Physically Cross-Linked and pH-Sensitive Polymeric Gels as Potential Vaginal Contraceptives
oleh: Ankit Rochani, Vivek Agrahari, Neelima Chandra, Onkar N. Singh, Timothy J. McCormick, Gustavo F. Doncel, Meredith R. Clark, Gagan Kaushal
Format: | Article |
---|---|
Diterbitkan: | MDPI AG 2022-04-01 |
Deskripsi
This study explored the development of cross-linked gels to potentially provide a physical barrier to vaginal sperm transport for contraception. Two types of gels were formulated, a physically cross-linked iota-carrageenan (C<sub>i</sub>) phenylboronic acid functionalized hydroxylpropylmethyacrylate copolymer (PBA)-based (C<sub>i</sub>-PBA) gel, designed to block vaginal sperm transport. The second gel was pH-shifting cross-linked C<sub>i</sub>-polyvinyl alcohol-boric acid (C<sub>i</sub>-PVA-BA) gel, designed to modulate its properties in forming a viscoelastic, weakly cross-linked transient network (due to C<sub>i</sub> gelling properties) on vaginal application (at acidic pH of ~3.5–4.5) to a more elastic, densely cross-linked (due to borate-diol cross-linking) gel network at basic pH of 7–8 of seminal fluid, thereby acting as a physical barrier to motile sperm. The gels were characterized for dynamic rheology, physicochemical properties, and impact on sperm functionality (motility, viability, penetration). The rheology data confirmed that the C<sub>i</sub>-PBA gel was formed by ionic interactions whereas C<sub>i</sub>-PVA-BA gel was chemically cross-linked and became more elastic at basic pH. Based on the screening data, lead gels were selected for in vitro sperm functionality testing. The in vitro results confirmed that the C<sub>i</sub>-PBA and C<sub>i</sub>-PVA-BA gels created a barrier at the sperm-gel interface, providing sperm blocking properties. For preclinical proof-of-concept, the C<sub>i</sub>-PBA gels were applied vaginally and tested for contraceptive efficacy in rabbits, demonstrating only partial efficacy (40–60%). Overall, the in vitro and in vivo results support the development and further optimization of cross-linked gels using commercially available materials as vaginal contraceptives.